Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

D. F. McDermott, B. I. Rini, R. J. Motzer, N. M. Tannir, B. Escudier, C. K. Kollmannsberger, H. J. Hammers, C. Porta, S. George, F. Donskov, H. P. Gurney, M.-O. Grimm, M. Harrison, T. E. Hutson, J. Doan, S. Yang, S. Rao, S. Mekan, A. Ambavane, T. Powles

Research output: Contribution to journalMeeting abstractpeer-review

8 Downloads (Pure)
Original languageEnglish
Pages (from-to)viii309
Number of pages1
JournalAnnals of Oncology
Issue numberSupplement 8
Publication statusPublished - 1 Oct 2018
Event43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany
Duration: 19 Oct 201823 Oct 2018

Bibliographical note

Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Cite this